Cadrenal Therapeutics, Inc. · NASDAQ:CVKD

Cadrenal Therapeutics, Inc. financial statements

Cadrenal Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2008
Revenue000
Cost of revenue1.88K220.1K1.27K220.1K
Gross profit-1.88K-1.98K-1.27K
Research and development4.10M4.21M4.08M392.9K200.0K
Selling, general and administrative9.35M6.75M3.55M
Operating income-13.5M-11.0M-7.63M-2.70M
Depreciation and amortization6.87K1.88K1.98K1.27K
EBITDA-13.5M-11.0M-7.63M-2.70M
Interest expense03.53K107.1K
Income before tax-13.2M-10.7M-8.36M-6.71M
Income tax-165.9K4
Net income-13.2M-10.7M-8.36M-6.71M
Earnings per share, basic-6.64-8.73-9.29-8.66
Earnings per share, diluted-6.64-8.73-9.29

Balance sheet

LineFY2025FY2024FY2023FY2022FY2008
Cash and equivalents4.01M10.0M8.40M32.6K
Receivables5.10K38.2K37.2K
Current assets4.32M10.1M8.49M727.6K
Property, plant and equipment5.17K6.94K2.29K44.6K
Total assets4.33M10.1M8.52M778.2K
Accounts payable650.7K1.50M167.3K404.9K
Current liabilities1.59M2.68M826.9K1.33M
Long-term debt553.3K
Total debt21.4K640.7K
Total liabilities1.59M2.68M826.9K6.33M
Shareholders' equity2.74M7.44M7.69M-5.55M
Shares outstanding2.34M1.78M868.2K775.6K11.7M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-12.6M-7.36M-3.53M-1.31M
Capital spending-5.10K-6.54K-3.25K-2.49K
Free cash flow-12.6M-7.36M-3.53M-1.32M
Cash from investing-5.10K-6.54K-3.25K-2.49K
Cash from financing6.60M8.98M11.9M1.35M
Share buybacks-291.9K0
Change in cash-6.01M1.62M8.37M32.6K